Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE RnRMarketResearch.com, TBC
DALLAS, February 21, 2014 /PRNewswire/ --
RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as monoclonal antibodies market forecasts in breast cancer, colorectal cancer as well as gastric and esophageal cancers to 2019.
There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, the report Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth forecasts the global market to grow to a value of $5.5 billion by 2019. Key late-stage pipeline products discussed in this research include IMC-1121B (Ramucirumab) - Eli Lilly and Company, Xilonix - Xbiotech, MetMAb (Onartuzumab) - Hoffmann-La Roche, Anti-DR5 MoAb (Tigatuzumab) - Daiichi Sankyo, MK0646 (Dalotuzumab) - Merck and AMG-655 (Conatumumab) - Amgen. Buy a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=136894 .
Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, the report Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth says the global market has potential to grow to a value of $766m by 2019. Providing 34 data tables and 51 figures, a brief introduction to the two indications, including the disease's pathogenesis, risk factors, diagnosis and treatment algorithms as well as in-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses, this report is available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=136895 .
The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, the report Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth predicts global market across the leading eight countries to have a potential to grow to a value of $10.6 billion by 2019. Promising drug candidates in the pipeline discussed in this report include
CDX-011 (glembatumumab vedotin) - Celldex Therapeutics, Metmab (onartuzumab) - Hoffman La Roche, Hu3S193 - Recepta Biopharma, MM-121 - Merrimack Pharmaceuticals, IMC-18F1 (Icrucumab) - Eli Lilly, Rexomun (Ertumaxomab) - Fresenius Biotech, Medi-573 (Dusigitumab) - Medimmune, MK-0646 (Dalotuzumab) - Merck and Co and LY3012217 (Cixutumumab) - Eli Lilly. Buy a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=127323 .
Global Cancer Monoclonal Antibodies Pipeline Analysis report gives comprehensive insight on the various Monoclonal Antibodies being developed for the treatment of Cancer. Research report covers all the ongoing Monoclonal Antibodies being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cancer Monoclonal Antibodies market based upon development process. Following parameters for each Monoclonal Antibodies drug profile in development phase are covered in "Global Cancer Monoclonal Antibodies Pipeline Analysis" research report:
Global Cancer Monoclonal Antibodies Drug Pipeline by Clinical Phase:
Buy a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=131238.
RnRMarketResearch.com is an online market research reports library (http://www.rnrmarketresearch.com/) of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
©2012 PR Newswire. All Rights Reserved.